Switch theme
Sign up to access all valuation multiples
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
2008
6.8K+
LTM Revenue $3.0B
LTM EBITDA -$1.5B
$7.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioNTech has a last 12-month revenue (LTM) of $3.0B and a last 12-month EBITDA of -$1.5B.
In the most recent fiscal year, BioNTech achieved revenue of $2.8B and an EBITDA of -$367M.
BioNTech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioNTech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0B | XXX | $2.8B | XXX | XXX | XXX |
| Gross Profit | $2.4B | XXX | $2.2B | XXX | XXX | XXX |
| Gross Margin | 80% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | -$1.5B | XXX | -$367M | XXX | XXX | XXX |
| EBITDA Margin | -51% | XXX | -13% | XXX | XXX | XXX |
| EBIT | -$1.9B | XXX | -$596M | XXX | XXX | XXX |
| EBIT Margin | -62% | XXX | -22% | XXX | XXX | XXX |
| Net Profit | -$1.2B | XXX | -$665M | XXX | XXX | XXX |
| Net Margin | -39% | XXX | -24% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BioNTech's stock price is $96.
BioNTech has current market cap of $23.0B, and EV of $7.5B.
See BioNTech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.5B | $23.0B | XXX | XXX | XXX | XXX | $-4.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BioNTech has market cap of $23.0B and EV of $7.5B.
BioNTech's trades at 2.7x EV/Revenue multiple, and -20.5x EV/EBITDA.
Equity research analysts estimate BioNTech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioNTech has a P/E ratio of -22.0x.
See valuation multiples for BioNTech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $23.0B | XXX | $23.0B | XXX | XXX | XXX |
| EV (current) | $7.5B | XXX | $7.5B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | -5.5x | XXX | -20.5x | XXX | XXX | XXX |
| EV/EBIT | -4.5x | XXX | -12.6x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -22.0x | XXX | -34.6x | XXX | XXX | XXX |
| EV/FCF | -14.3x | XXX | -30.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioNTech's last 12 month revenue growth is -12%
BioNTech's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
BioNTech's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioNTech's rule of X is -80% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioNTech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -12% | XXX | -4% | XXX | XXX | XXX |
| EBITDA Margin | -51% | XXX | -13% | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | -25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -80% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 82% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 102% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioNTech acquired XXX companies to date.
Last acquisition by BioNTech was XXXXXXXX, XXXXX XXXXX XXXXXX . BioNTech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BioNTech founded? | BioNTech was founded in 2008. |
| Where is BioNTech headquartered? | BioNTech is headquartered in United States of America. |
| How many employees does BioNTech have? | As of today, BioNTech has 6.8K+ employees. |
| Who is the CEO of BioNTech? | BioNTech's CEO is Professor Ugur Sahin, M.D.. |
| Is BioNTech publicy listed? | Yes, BioNTech is a public company listed on NAS. |
| What is the stock symbol of BioNTech? | BioNTech trades under BNTX ticker. |
| When did BioNTech go public? | BioNTech went public in 2019. |
| Who are competitors of BioNTech? | Similar companies to BioNTech include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of BioNTech? | BioNTech's current market cap is $23.0B |
| What is the current revenue of BioNTech? | BioNTech's last 12 months revenue is $3.0B. |
| What is the current revenue growth of BioNTech? | BioNTech revenue growth (NTM/LTM) is -12%. |
| What is the current EV/Revenue multiple of BioNTech? | Current revenue multiple of BioNTech is 2.8x. |
| Is BioNTech profitable? | Yes, BioNTech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BioNTech? | BioNTech's last 12 months EBITDA is -$1.5B. |
| What is BioNTech's EBITDA margin? | BioNTech's last 12 months EBITDA margin is -51%. |
| What is the current EV/EBITDA multiple of BioNTech? | Current EBITDA multiple of BioNTech is -5.5x. |
| What is the current FCF of BioNTech? | BioNTech's last 12 months FCF is -$591M. |
| What is BioNTech's FCF margin? | BioNTech's last 12 months FCF margin is -20%. |
| What is the current EV/FCF multiple of BioNTech? | Current FCF multiple of BioNTech is -14.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
